If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Pharma is bringing the respiratory world together

    Quick Contact
    • Aptar Pharma
    Aptar Pharma is bringing the respiratory world together
    Europe, Iberia, Portugal, Health, Pharmaceuticals, Product Development Services, Shows, Associations, Media

    Aptar Pharma is pleased to announce the co-organization and diamond sponsorship of the Respiratory Drug Delivery (RDD®) Europe 2019 scientific conference, which will connect pulmonary and nasal drug delivery experts from around the world in Estoril, Portugal, May 7-10, 2019.

    Bringing the Respiratory World Together

    Respiratory Drug Delivery Europe is a major conference bringing together experts from around the world to exchange emerging scientific knowledge and provide a dynamic forum for business networking. Approximately 500 delegates from 31 countries attended the 2017 edition in Antibes, France.

    RDD Europe attracts high level academic, industrial and regulatory scientists, and clinicians. It is a must-attend conference for companies involved in the research, development, testing and marketing of medicines, devices and services associated with pulmonary or nasal products.

    A premium, interactive three-day conference

    This year, the conference will kick-off with a plenary lecture entitled “Emerging Treatment Guidelines in COPD: Unravelling the Triple Therapy Trials,” delivered by Jadwiga Wedzicha, M.D. Professor of Respiratory Medicine, National Heart and Lung Institute, Imperial College London.

    Subsequent sessions will focus on:

    - New Approaches to Treating Old Diseases
    - Pipes, Particles and Predictions: New Insights into Deposition
    - Re-Inventing Inhalers for the Digital Age
    - Take a Deep Breath: Brexit and Environmental Sustainability
    - New Approaches to Inhalation Product Development and Production

    As part of the conference, RDD Europe 2019 will underline innovative research contributions via both podium and scientific poster sessions. Scientific posters will highlight recent nasal and pulmonary pharmaceutical research, with five of the best posters showcased during “Posters on the Podium”, a fast-paced interactive session. All accepted graduate student poster abstracts are automatically eligible for the VCU RDD Peter R. Byron Graduate Student Award.

    RDD Europe 2019 will also host 12 workshops led by drug delivery device experts and service providers. Workshops are a unique opportunity for focused scientific and technical exchange on work-in-progress and hot topics. Delegates can choose from the selection of interactive technical workshops highlighting a variety of innovative technologies, products and services impacting the industry.

    Valuable networking opportunities

    RDD Europe 2019 offers numerous networking opportunities including the Technology Exhibition, where exhibitors display innovative technologies and services throughout the conference in RDD’s signature table-top format. Device and equipment designers, service providers, and consultants will be on hand to interact and share their knowledge.

    A networking welcome cocktail reception will take place on the evening of May 7, and a Gala Dinner sponsored by Aptar Pharma will take place on Thursday, May 9 at a scenic location in Lisbon.

    RDD Europe conferences have reached capacity in the past, so early registration is strongly recommended. The early bird rate will be available until January 21, 2019.

    Further information about RDD Europe 2019, including the full program and registration details, is available at https://www.rddonline.com/rddeurope2019.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 15 Jan 2019
    • Hits 1408
    Sun-Rain
    APG
    Epopack